Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash from Financing Activities (2020 - 2025)

Bioventus (BVS) has disclosed Cash from Financing Activities for 6 consecutive years, with -$28.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 33.62% year-over-year to -$28.4 million, compared with a TTM value of -$62.1 million through Dec 2025, down 13.85%, and an annual FY2025 reading of -$62.1 million, down 13.85% over the prior year.
  • Cash from Financing Activities was -$28.4 million for Q4 2025 at Bioventus, down from -$20.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $176.3 million in Q4 2021 and bottomed at -$62.2 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $9.6 million, with a median of -$2.1 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 1884.86% in 2021, then crashed 306007.14% in 2024.
  • Year by year, Cash from Financing Activities stood at $176.3 million in 2021, then tumbled by 103.08% to -$5.4 million in 2022, then skyrocketed by 99.74% to -$14000.0 in 2023, then plummeted by 306007.14% to -$42.9 million in 2024, then skyrocketed by 33.62% to -$28.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BVS at -$28.4 million in Q4 2025, -$20.0 million in Q3 2025, and -$14.7 million in Q2 2025.